Document is current
Any future updates will be listed below
-
Authors
Metcalfe, Riley D.
Hanssen, Eric https://orcid.org/0000-0002-4064-1844
Fung, Ka Yee
Aizel, Kaheina
Kosasih, Clara C. https://orcid.org/0000-0003-3249-7341
Zlatic, Courtney O.
Doughty, Larissa
Morton, Craig J. https://orcid.org/0000-0001-5452-5193
Leis, Andrew P.
Parker, Michael W. https://orcid.org/0000-0002-3101-1138
Gooley, Paul R. https://orcid.org/0000-0002-0323-449X
Putoczki, Tracy L.
Griffin, Michael D. W. https://orcid.org/0000-0001-9845-7735
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (APP1147621, APP1080498, APP1194263, APP1147621, APP1080498)
Cancer Council NSW (RG 22-01, RG 22-01)
Department of Education and Training | Australian Research Council (DP230102422, DP230102422)
- License Information
-
More Information
Article History
Received: 31 October 2022
Accepted: 20 October 2023
First Online: 20 November 2023
Competing interests
: T.L.P. has consulted for enterprises involved in biological drug development (Mestag Therapeutics, Enleofen Ltd). M.D.W.G. has consulted for enterprises involved in biological drug development (Mestag Therapeutics). T.L.P. and M.D.W.G. are founders of Nelcanen Therapeutics Pty Ltd. Other authors declare that they have no conflicts of interest.
